Research analysts covering Inhibitor Therapeutics.
Recent press releases and 8-K filings for INTI.
Exelixis Announces Positive Phase 3 STELLAR-303 Trial Results
INTI
New Projects/Investments
- Exelixis announced detailed results from the STELLAR-303 phase 3 pivotal trial, demonstrating that zanzalintinib in combination with atezolizumab improved median overall survival to 10.9 months compared to 9.4 months with regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer, significantly reducing the risk of death by 20%.
- The overall survival benefit was consistently observed across pre-specified subgroups, including geographic region, RAS status, liver involvement, and prior anti-VEGF therapy.
- The safety profiles of the combination were generally consistent with previous observations, with Grade 3/4 treatment-related adverse events occurring in 59% of patients receiving zanzalintinib in combination with atezolizumab and 37% of patients receiving regorafenib.
- Exelixis plans to complete its first new drug application submission for zanzalintinib in the U.S. in 2025.
Oct 20, 2025, 6:30 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more